Please login to the form below

Not currently logged in
Email:
Password:

Fabrazyme

This page shows the latest Fabrazyme news and features for those working in and with pharma, biotech and healthcare.

Amicus Therapeutics launches Fabry treatment Galafold in Italy

Amicus Therapeutics launches Fabry treatment Galafold in Italy

Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta).

Latest news

  • Amicus gets NICE green light for Fabry drug Amicus gets NICE green light for Fabry drug

    Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta) and Shire's Replagal

  • NICE backs Amicus Therapeutics’ Galafold NICE backs Amicus Therapeutics’ Galafold

    Despite initial uncertainty over its clinical effectiveness, the cost-effectiveness watchdog concluded that Galafold provides enough similar benefits to current enzyme replacement therapies (ERT), such as Sanofi's Fabrazyme (agalsidase beta)

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    The drug could offer a patient-friendly alternative to injectable Fabry therapies such as Sanofi/Genzyme's Fabrazyme (agalsidase beta) and Shire's Replagal (agalsidase alfa).

  • Sanofi rare disease drug a breakthrough, says FDA Sanofi rare disease drug a breakthrough, says FDA

    Genzyme has built the core of its business by focusing on this group, developing big-selling brands such as Gaucher therapy Cerezyme (imiglucerase alfa), Fabrazyme (agalsidase beta) for Fabry disease and

  • Sanofi gains accelerated review for rare disease drug Sanofi gains accelerated review for rare disease drug

    The FDA has granted a speedy review for Sanofi's new Fabry disease pill as the next generation version of its marketed treatment Fabrazyme. ... Sanofi's new pill is the next-gen version of Fabrazyme, which is an enzyme replacement therapy and given by

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics